Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.
Canada’s non-profit advocacy organisation TheraPsil has announced the launch of its MDMA-assisted psychotherapy training programme.
In the face of escalating climate, economic and mental health crises, millions are seeking legal, safe ways to experience magic mushrooms (psilocybin) and other psychoactive plant...
Japanese pharmaceutical company Otsuka Pharmaceutical has made one of Big Pharma’s first pivots into the psychedelics space with the acquisition of Mindset Pharma.
Cybin Inc.
The Indigenous Medicine Conservation Fund (IMC Fund) took part in the 2023 Parliament of the World’s Religions (PoWR) held at McCormick Place Lakeside Center in Chicago,...
Enveric Biosciences has confirmed it has completed the manufacture of its lead drug candidate – EB-373 – a New Chemical Entity (NCE) designed as a next-generation...
Cybin Inc.
UK-based COMPASS Pathways has secured $285 million in funding through a private placement to support its research in psychedelic medicines.
The first-ever Professional Practice Guidelines for psychedelic therapy in the US have been published by the American Psychedelic Practitioners Association (APPA) and BrainFutures.